11 IPOs priced during the week of September 29, but only 3 had any meaningful gains, including two tech deals and American Addiction Centers, a network of substance abuse treatment centers. The group raised $2.4 billion; 25% less than expected after frac sand...read more
Calithera Biosciences, an early-stage biotech developing a drug platform that inhibits tumor metabolism, raised $80 million by offering 8 million shares (upsized from 6 million) at $10, below the range of $13 to $15. Calithera Biosciences plans to list on the...read more
Calithera Biosciences, a early-stage biotech developing a drug platform that inhibits tumor metabolism, announced terms for its IPO on Friday. The San Francisco, CA-based company plans to raise $84 million by offering 6 million shares at a price range of $13 to...read more
US IPO Pricing Recap: 11 IPOs trade poorly but investors can't get enough American Addiction
11 IPOs priced during the week of September 29, but only 3 had any meaningful gains, including two tech deals and American Addiction Centers, a network of substance abuse treatment centers. The group raised $2.4 billion; 25% less than expected after frac sand...read more
Calithera Biosciences prices IPO at $10, below the range
Calithera Biosciences, an early-stage biotech developing a drug platform that inhibits tumor metabolism, raised $80 million by offering 8 million shares (upsized from 6 million) at $10, below the range of $13 to $15. Calithera Biosciences plans to list on the...read more
11 IPOs planned for the week of September 29; 4th quarter kicks off with a $1 billion IPO
Heightened IPO activity continues with 11 IPOs set to raise $3.2 billion this week, following the ...read more
Calithera Biosciences sets terms for $84 million IPO
Calithera Biosciences, a early-stage biotech developing a drug platform that inhibits tumor metabolism, announced terms for its IPO on Friday. The San Francisco, CA-based company plans to raise $84 million by offering 6 million shares at a price range of $13 to...read more